Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study

The Lancet Oncology
Akira KawaiShunji Takahashi

Abstract

Trabectedin binds to the minor groove of DNA and blocks DNA repair machinery. Preclinical data have shown that trabectedin also modulates the transcription of the oncogenic fusion proteins of translocation-related sarcomas. We aimed to assess the efficacy and safety of trabectedin as second-line therapy or later for patients with advanced translocation-related sarcoma. We did a multicentre randomised open-label study in Japan. Eligible patients had pathological diagnosis of translocation-related sarcoma, were aged 19 years or older, were unresponsive or intolerant to standard chemotherapy regimens, no more than four previous chemotherapy regimens, Eastern Cooperative Oncology Group performance status 0 or 1, adequate bone marrow reserve, renal and liver functions, and had measurable lesions. Patients were randomly assigned (1:1) by the minimisation method to receive either trabectedin (1·2 mg/m(2) given via a central venous line over 24 h on day 1 of a 21 day treatment cycle) or best supportive care, which was adjusted centrally by pathological subtype. Investigators, patients, and the sponsor were unmasked to the treatment assignment. Progression-free survival and objective responses were assessed by a masked central radiology...Continue Reading

References

Mar 2, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M Van GlabbekeUNKNOWN EORTC Soft Tissue and Bone Sarcoma Group
Aug 19, 2005·The New England Journal of Medicine·Matthew A ClarkJ Meirion Thomas
Dec 20, 2005·Histopathology·C R Antonescu
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boris FreidlinJo Anne Zujewski
Jul 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul LoriganUNKNOWN European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Feb 5, 2009·Molecular Cancer Therapeutics·Claudia ForniRoberto Mantovani
Aug 12, 2009·Seminars in Oncology·Fredrik MertensThor Alvegård
Jul 22, 2010·Molecular Cancer Therapeutics·Maurizio D'Incalci, Carlos M Galmarini
Jun 7, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GronchiJ Y Blay
Dec 24, 2011·Pathology International·Yasuhiro MiuraTadashi Hasegawa
Jul 4, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Axel Le CesneGeorge D Demetri
May 10, 2013·Expert Review of Anticancer Therapy·Axel Le Cesne
Aug 14, 2013·Expert Opinion on Drug Safety·Juan Martin-Liberal, Ian Judson
Feb 12, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Jean-Yves BlaySant P Chawla
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group

❮ Previous
Next ❯

Citations

Nov 26, 2015·Expert Opinion on Investigational Drugs·Maurizio D'Incalci, Alberto Zambelli
Feb 13, 2016·The Lancet Oncology·Jean-Yves BlayIsabelle Ray-Coquard
Jan 20, 2016·Bulletin du cancer·Nicolas MagnéStéphane Vignot
Nov 26, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C PeugniezN Penel
Sep 20, 2015·Bulletin du cancer·Guillaume MoriceauNicolas Magné
Mar 22, 2015·The Lancet Oncology·Peter Hohenberger
May 29, 2016·Advances in Therapy·Erlinda M GordonSant P Chawla
Oct 21, 2016·Oncoimmunology·Erika VacchelliLorenzo Galluzzi
Sep 13, 2016·Expert Opinion on Pharmacotherapy·Ritika Zijoo, Margaret von Mehren
Oct 25, 2016·Cancer Treatment Reviews·Bradley J MonkMaurizio D'Incalci
Dec 6, 2016·Future Oncology·George D DemetriPaolo G Casali
Dec 6, 2016·Future Oncology·Javier Martín BrotoPeter Reichardt
Jan 21, 2017·Expert Review of Anticancer Therapy·Akash TiwariSameer Bakhshi
Mar 24, 2017·Current Treatment Options in Oncology·Alexander T J LeeRobin L Jones
Feb 28, 2017·Cancer·Robert M HoffmanFritz C Eilber
Apr 21, 2017·Expert Review of Anticancer Therapy·E SkafidaA Digklia
Mar 8, 2018·International Journal of Molecular Sciences·Kenji Nakano, Shunji Takahashi
Nov 1, 2017·International Journal of Clinical Oncology·Hiroshi KobayashiSakae Tanaka
May 17, 2018·Future Oncology·Isabelle Ray-CoquardSebastian Bauer
Dec 1, 2017·Immunotherapy·Shinji MiwaHiroyuki Tsuchiya
Apr 14, 2017·The Cochrane Database of Systematic Reviews·Frank PeinemannLesley A Smith
Jun 3, 2017·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Gabriella FerrandinaGiovanni Scambia
Jan 10, 2019·International Journal of Molecular Sciences·Shinji MiwaHiroyuki Tsuchiya
Nov 23, 2018·International Journal of Clinical Oncology·Hiroshi KobayashiSakae Tanaka
Oct 19, 2017·Journal of Surgical Oncology·Yusuke TsudaAkira Kawai
Dec 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alex Thomas John LeeRobin Lewis Jones
Jan 23, 2020·Cancers·Kenji Nakano, Shunji Takahashi
Oct 13, 2016·Oncotarget·Amanda R DancsokTorsten O Nielsen
Jun 9, 2020·Clinical and Translational Medicine·Fan TangXiawei Wei
Jun 2, 2016·American Society of Clinical Oncology Educational Book·Alex LeeSeth M Pollack
Sep 16, 2020·Expert Review of Anticancer Therapy·Luis Miguel de Sande GonzálezAxel Le Cesne
Jun 1, 2019·International Cancer Conference Journal·Etsuko FujimotoNorihiro Teramoto
Aug 14, 2019·Oncology Letters·Jose Duran-MorenoAnna Koumarianou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.